Bernardo H.L. Goulart, MD, on Stage IV NSCLC: High Drug Costs May Affect Survival
2019 Quality Care SymposiumBernardo H. L. Goulart, MD, of Seattle Cancer Care Alliance, discusses his findings that high out-of-pocket costs for oral tyrosine kinase inhibitors may lower survival rates, shorten the duration of therapy, and reduce the number of prescriptions for patients with metastatic EGFR- or ALK-positive non–small cell lung cancer (Abstract 3).
Related Videos
Cary P. Gross, MD, on Creating and Implementing Clinical Pathways: Where is the Patient’s Voice?
Cary P. Gross, MD, of Yale School of Medicine, discusses the challenges of implementing pathways and guiding patient decision-making on treatment.
Ryan Huey, MD, on the Financial Toxicity of Early-Phase Clinical Trials
Ryan Huey, MD, of The University of Texas MD Anderson Cancer Center, discusses his findings that showed the large financial burden on lower-income patients enrolled in phase ...
Linda D. Bosserman, MD, on Pathways for Personalized Precision Medicine and Value
Linda D. Bosserman, MD, of City of Hope, discusses guidelines vs pathways, how to personalize pathways, integrated diagnostics, supportive care regimens, and financial guidan...
Mallika Sharma, MPH, on Eliminating Prior Authorizations, Anxiety, Delay in Care, Higher Costs
Mallika Sharma, MPH, of Seattle Cancer Care Alliance, discusses her findings that, by doing away with the many prior authorization denials based on administrative errors, pro...
Lauren M. Hamel, PhD, on Race and Doctor-Patient Behavior
Lauren M. Hamel, PhD, of Wayne State University/Karmanos Cancer Institute, discusses her findings on the ways in which nonverbal behavior between doctors and patients of the ...
